Background Recent evidence has identified limited naloxone accessibility in community
pharmacies. Objectives To summarize current literature regarding naloxone accessibility …

Background Community pharmacies are an important resource for people who inject drugs
(PWID) to purchase over-the-counter (OTC) syringes. Access to sterile injection equipment …

Background Prompt access to prescribed buprenorphine/naloxone films (BUP/NX) and
naloxone nasal spray (NNS) is vital for patients with opioid use disorder (OUD), but multiple …

Background Increasing buprenorphine prescribing for opioid use disorder (OUD) has been
a major focus of US opioid response efforts. However, concerns related to dispensing …

Objective: People with substance use disorders (SUDs) are faced with pervasive stigma.
Education-based interventions tend to emphasize biological causes of dependency; …

Background People who use drugs (PWUD) frequently delay or avoid obtaining medical
care in traditional healthcare settings. Through a randomized controlled trial, we …

In the last decade, the US opioid overdose crisis has magnified, particularly since the
introduction of synthetic opioids, including fentanyl. Despite the benefits of medications for …

Access to the opioid antidote naloxone is a critical component of addressing the opioid
crisis. Naloxone is a population-level prevention intervention associated with substantial …

The COVID-19 pandemic triggered unprecedented expansion of telemedicine, including in
the delivery of opioid agonist treatment (OAT) for people with opioid use disorder (OUD) …

Background While barriers to accessing buprenorphine (BUP) therapy have been well
described, little is known about pharmacy-related barriers. The objective of this study was to …